Business
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
DALLAS, January 12, 2026--A.I. center of excellence - Lantern Pharma
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/84f07890448731878f19132e16a0c220"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UbsuMvZSi0t6IBisV285xw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/84f07890448731878f19132e16a0c220","width":480,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration with global biopharma customers and partners.","length":241,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This strategic initiative positions Lantern to scale its proven AI capabilities and platform across oncology and into new disease categories, meeting growing biopharma partner demand.","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Hiring for initial positions has already been initiated and Lantern anticipates that expansion and hiring will be cash flow neutral to the Company.","length":147,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":571,"olType":false},{"type":"text","content":"DALLAS, January 12, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneer in AI-driven precision oncology and computational therapeutic development, today announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India. This strategic initiative represents a critical inflection point in Lantern's evolution—transitioning from pioneering AI-enabled drug discovery in cancer to industrializing those capabilities at global scale for the broader drug development community.","length":532,"tagName":"p"},{"type":"text","content":"As pharmaceutical companies increasingly shift from AI experimentation to enterprise-scale deployment, Lantern's Bengaluru center will serve as the company's global scale-up center for the AI platform, providing expanded computational capacity, specialized technical talent, and follow-the-sun development cycles that enable rapid iteration and deployment of advanced AI ...